Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M409596200 on December 28, 2004

J. Biol. Chem., Vol. 280, Issue 11, 10357-10367, March 18, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
280/11/10357    most recent
M409596200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yadav, V. K.
Right arrow Articles by Medhamurthy, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yadav, V. K.
Right arrow Articles by Medhamurthy, R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Prostaglandin F2{alpha}-mediated Activation of Apoptotic Signaling Cascades in the Corpus Luteum during Apoptosis

INVOLVEMENT OF CASPASE-ACTIVATED DNase*{boxs}

Vijay K. Yadav{ddagger}, Garimella Lakshmi, and Rudraiah Medhamurthy§

From the Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore 560 012, India

Received for publication, August 20, 2004 , and in revised form, December 20, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Prostaglandin F2{alpha} (PGF2{alpha}) acting via a G protein-coupled receptor has been shown to induce apoptosis in the corpus luteum of many species. Studies were carried out to characterize changes in the apoptotic signaling cascade(s) culminating in luteal tissue apoptosis during PGF2{alpha}-induced luteolysis in the bovine species in which initiation of apoptosis was demonstrable at 18 h after exogenous PGF2{alpha} treatment. An analysis of intrinsic arm of apoptotic signaling cascade elements revealed that PGF2{alpha} injection triggered increased ratio of Bax to Bcl-2 in the luteal tissue as early as 4 h posttreatment that remained elevated until 18 h. This increase was associated with the elevation in the active caspase-9 and -3 protein levels and activity (p < 0.05) at 4–12 h, but a spurt in the activity was seen only at 18 h posttreatment that could not be accounted for by the changes in the Bax/Bcl-2 ratio or changes in translocation of Bax to mitochondria. Examination of luteal tissue for FasL/Fas death receptor cascade revealed increased expression of FasL and Fas at 18 h accompanied by a significant (p < 0.05) induction in the caspase-8 activity and truncated Bid levels. Furthermore, intrabursal administration of specific caspase inhibitors, downstream to the extrinsic and intrinsic apoptotic signaling cascades, in a pseudopregnant rat model revealed a greater importance of extrinsic apoptotic signaling cascade in mediating luteal tissue apoptosis during PGF2{alpha} treatment. The DNase responsible for PGF2{alpha}-induced apoptotic DNA fragmentation was found to be Ca2+/Mg2+-dependent, temperature-sensitive DNase, and optimally active at neutral pH conditions. This putative DNase was inhibited by the recombinant inhibitor of caspase-activated DNase, and immunodepletion of caspase-activated DNase from luteal lysates abolished the observed DNA fragmentation activity. Together, these data demonstrate for the first time temporal and spatial changes in the apoptotic signaling cascades during PGF2{alpha}-in-duced apoptosis in the corpus luteum.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Although PGF2{alpha}1 was discovered as a physiological luteolysin nearly three decades ago (1), cellular events associated with luteolysis remain poorly characterized, in part because of the lack of availability of a suitable in vitro model system that mimics all of the cellular events that occur in vivo in response to spontaneous or PGF2{alpha}-induced luteolysis (2). Prostaglandin F2{alpha} interacts with its G protein-coupled receptor, present predominantly on large luteal cells, but are also present on small luteal and endothelial cells of the corpus luteum (3) and activates Gq/phospholipase C/protein kinase C pathway (4, 5), resulting in decreased steroidogenesis; The intracellular signaling events that lead to structural regression of luteal tissue are poorly characterized; however, it is now well established that apoptosis or programmed cell death plays a central role in the structural regression of luteal tissue during PGF2{alpha}-induced or spontaneous luteolysis of several species (6–10).

Apoptosis or programmed cell death is an evolutionarily conserved mechanism orchestrated by the genome-encoded proteins of the host that form part of two distinct (intrinsic and extrinsic) signaling cascades. The intrinsic apoptotic signaling cascade is generally thought to be activated by apoptotic stimuli that originate within a cell in response to certain drugs, radiation, or growth factor withdrawal and primarily cause changes in mitochondrial permeability through alterations in the ratio of pro-apoptotic to anti-apoptotic Bcl-2 family members (11). On the other hand, the extrinsic apoptotic signaling cascade is activated by extracellular signals (viz. FasL) that interact with cell surface receptors (viz. Fas) to induce cell death (12). Changes in the mitochondrial permeability or death receptor activation lead to activation of a cascade of intracellular proteases known as caspases (13). Once activated, caspases cleave various cellular substrates including actin, poly(ADP-ribose) polymerase (PARP), DFF45/inhibitor of caspase-activated DNase (ICAD), fodrin, and lamin that contribute to the morphological changes seen in apoptotic cells (13).

Fragmentation of DNA constitutes the final cellular event during apoptosis. It is mediated by the internucleosomal cleavage of DNA by endonucleases resulting in the formation of a 180-bp DNA ladder, which is considered as one of the hallmarks of cellular apoptosis. Candidates for such endonucleases include the caspase-activated enzymes, such as DFF40/caspase-activated DNase (CAD) (14, 15) and Nuc70 (16), divalent cation-dependent neutral (17) or acidic endonucleases (18), and Ca2+/Mg2+-dependent endonucleases (19–21). Recently, however, another DNase, endonuclease G, released from mitochondria during apoptosis has also been shown to mediate apoptotic DNA fragmentation (22).

Unlike the classical cell surface receptors that induce cell death, PGF2{alpha} receptor is a G protein-coupled receptor that lacks any intracytoplasmic region with an identity/similarity to the death domain/caspase activation and recruitment domain that recruits and/or activates caspases. However, caspase-8, one of the initiator caspases acting downstream of the Fas receptor pathway, has recently been reported to be activated during PGF2{alpha}-induced luteal tissue apoptosis in the corpus luteum of murine species (23) and the authors hypothesized that some level of cross-talk exists between PGF2{alpha} receptor signal transduction and the classical apoptotic signaling cascades. This hypothesis is further strengthened by the observation that increased Bax and Fas expressions have been reported to be associated with the apoptosis in spontaneously regressing luteal tissue of the non-fertile cycles, whereas a significant attenuation in expression in these genes are seen in the corpus luteum during fertile cycle in the bovine species (24, 25). Also, several in vitro studies indicate that apoptotic stimuli such as soluble FasL (25, 26), serum withdrawal (6), interferon-{gamma} (27), and tumor necrosis factor-{alpha} (25, 28) that activate classical apoptotic signaling cascades are capable of inducing apoptosis in the luteal cells. The final phase of cellular demise, i.e. fragmentation of DNA, is very well characterized in the luteal tissue and is frequently used as an index of structural luteal regression. However, the nature of the DNase that executes DNA fragmentation during PGF2{alpha}-induced apoptosis in the luteal tissue has not been identified, although several DNase-like activities, viz. Ca2+/Mg2+-dependent DNase (29), Zn2+-inhibitable DNase (6), and DNase I-like enzymes (30), have been observed to be active in the luteal cells under different conditions. These studies indicate that elements of apoptotic signaling cascades are present in the luteal cells, but the sequence of events that commit luteal cells to apoptosis in response to PGF2{alpha} remains to be determined.

The purpose of this study was to systematically analyze the involvement of classical apoptotic signaling cascades during PGF2{alpha}-mediated apoptotic cell death in the corpus luteum. Moreover, the biochemical nature of the endonuclease responsible for apoptotic DNA fragmentation in the corpus luteum in response to PGF2{alpha} has not been previously studied and represents the major focus of our investigation. We chose to study these pathways in the corpus luteum of buffalo cows (Bubalus bubalis), because the characterization of apoptosis following spontaneous or PGF2{alpha}-induced luteolysis in this species was reported recently (7). Our results show for the first time that PGF2{alpha}-mediated apoptosis in the corpus luteum involves the activation of mitochondrial apoptotic signaling cascade that precedes the activation of FasL/Fas cascade during PGF2{alpha}-induced apoptotic cell death in the bovine corpus luteum. A pseudopregnant rat model was standardized to investigate the relative roles of intrinsic and extrinsic apoptotic signaling cascades in PGF2{alpha}-induced luteal tissue apoptosis. Using the pseudopregnant rat model, we demonstrate that intrabursal injection of a peptide-based cell-permeable caspase-8 inhibitor (Z-IETD-fmk) prior to PGF2{alpha} injection abolished the caspase-3 activity and DNA fragmentation during PGF2{alpha}-induced luteal tissue apoptosis, whereas intrabursal injection of caspase-9 inhibitor (Z-LEHD-fmk) only attenuated the apoptosis. Moreover, our results point to an important role played by CAD in mediating apoptotic DNA fragmentation during PGF2{alpha}-induced luteolysis.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Reagents
The polyclonal antibodies specific to Bcl-2 (number 197207), Bax (number 196820), phospho-BAD (number 9291), BAD (number 9292), cleaved caspase-9 (number 9501S), cleaved caspase-3 (number 9661S), Bid (number 2002), and ICAD (number PC366T) were purchased from Calbiochem (numbers 197207, 196820, and PC366T) and Cell Signaling Technology (Beverly, MA) (numbers 9291, 9292, 9501S, 9661S, and 2002). PARP antibody (AM30) was purchased from Oncogene Research Products (Boston, MA). Caspase-activated DNase antibody (Ab8406) was purchased from Abcam Inc. (Cambridge, MA). {beta}-Actin antibody (A5441) was purchased from Sigma. Caspase substrates and inhibitors (Z-DEVD-AFC (caspase-3 substrate 264150), Z-IETD-AFC (caspase-8 substrate 368059), Z-LEHD-AFC (caspase-9 substrate 218765), Ac-DEVD-CHO (caspase-3 inhibitor 235420), Z-IE(OMe)TD(OMe)-fmk (caspase-8 inhibitor 218759), Z-LE(OMe)HD(OMe)-fmk (caspase-9 inhibitor 218761), and Z-VAD(OMe)-fmk (General executionary caspase (caspase-1, -3, -4, and -7) inhibitor 627610) were purchased from Calbiochem. In situ apoptosis analysis kit (number 1684809) was purchased from Roche Diagnostics (Mannheim, Germany). The expression plasmid for glutathione S-transferase (GST)-ICAD-L (see Ref. 14 for details of the vector) was a kind gift from Professor S. Nagata (Department of Genetics, Osaka University Medical School, Osaka, Japan). Glutathione-Sepharose 4B and pGEX-5X3 (GST expression plasmid) were obtained from Amersham Biosciences. GeneScreen Plus and PVDF membranes were purchased from PerkinElmer Life Sciences. All of the other reagents were purchased from Sigma or Invitrogen or sourced locally.

Animal Models and Methods
A. PGF2{alpha}-induced Luteal Tissue Apoptosis in the Buffalo Cows (B. bubalis)—All of the procedures in animals were approved by the Institutional Animal Ethics Committee (Indian Institute of Science). Buffalo cows (B. bubalis) on day 11 of the estrous cycle were injected intramuscular with 750 µg of Tiaprost (Iliren®, Intervet International B.V., Boxmeer, Holland), a synthetic analog of PGF2{alpha} (n = 3–4 animals/time point). At 4, 12, and 18 h following PGF2{alpha} injection, ovaries were collected in cold phosphate-buffered saline and washed in phosphate-buffered saline prior to processing. Under sterile conditions, the corpus luteum from the ovary was extirpated, cut into 6–8 pieces, transferred to labeled cryovials, flash-frozen in liquid nitrogen, and stored at –70 °C until analysis. Also, a small portion of corpus luteum tissue was fixed in Bouin's solution for histological examination.

B. PGF2{alpha}-induced Luteal Tissue Apoptosis in the Pseudopregnant Rats: Effect of Caspase Inhibitors—Adult rats (Wistar strain) were housed in a controlled environment (22–24 °C) and kept under a photoperiod of 14-h light and 10 h of darkness with ad libitum access to food and water. Pseudopregnancy was induced in the female rats by cohabitation with vasectomized male rats on the afternoon of pro-estrus. Following cohabitation, female rats were examined for the presence of vaginal plug and/or subjected to screening of vaginal smears daily for the extension of the di-estrus period. The presence of vaginal plug/day 1 of continuous di-estrus (at least for 3 days) following cohabitation with the vasectomized male rats was considered as day 1 of pseudopregnancy. In addition, pseudopregnancy was also confirmed by serum progesterone analysis on day 5 of pseudopregnancy. Only the females showing serum progesterone, >50 ng/ml were used in the study. On day 8 of pseudopregnancy, female rats were anesthetized with pentobarbital sodium (7.5 mg/rat, intraperitoneal) and abdominal cavity was accessed through two dorsolateral subrenal incisions. The ovary with the surrounding tissues was exposed, and a 30-gauge needle attached to a 1-ml tuberculin syringe was gently entered into the ovarian bursa. Different caspase inhibitors (dissolved in Me2SO) diluted in 0.15 M NaCl solution or vehicle solution for the respective inhibitors (15 µg/ovary) were injected into the ovarian bursal cavity in a volume of 60 µl. Only animals with the swelling of bursa and no visible leakage of the injected fluids were included in the study (n = 3 rats/treatment group). The intrabursal route of administration has been utilized in various in vivo studies to deliver different drugs to the ovary (31–33). After the completion of the injection procedure, ovaries were returned to the abdominal cavity and the abdominal wall was sutured with absorbable suture and the skin with the surgical clips. Immediately after surgery (15 min), rats received (subcutaneous) either PGF2{alpha} (15 µg of cloprostenol, Estrumat, Pitman-Moore Ltd., Harefield, United Kingdom) diluted in 0.3 ml of 0.15 M NaCl or 0.3 ml of 0.15 M NaCl (vehicle) treatment. The animals were killed 24 h later, and the ovaries were visualized under a dissecting microscope and processed for corpora lutea collection. Corpora lutea were snap-frozen in liquid nitrogen and stored at –70 °C until analysis. The doses of peptide-based cell-permeable caspase inhibitors used in this study were prepared based on the previous studies where as few as 300 ng of caspase inhibitors/rat have been found to effectively block apoptosis in several in vivo models of apoptosis when injected directly into the tissue of interest (34–38). The luteolytic dose of PGF2{alpha} employed in this study was based on a previous study in the pseudopregnant rat model (39).

In Situ Apoptosis Analysis, DNA fragmentation Analysis, and Immunohistochemistry
Corpora lutea were processed for in situ apoptosis analysis according to the manufacturer's recommendations. DNA fragmentation analysis and immunohistochemistry using Bax polyclonal antibody were carried out as described previously by us (7).

RNA Extraction and Semi-quantitative RT-PCR Analysis
Total RNA was extracted from luteal tissue using TRIzol reagent according to the manufacturer's recommendations. The quality and quantity of each RNA sample were assessed spectrophotometrically and on a 1% formaldehyde-agarose gel. Semi-quantitative RT-PCR was carried out essentially as described previously (40). Oligonucleotide primers were designed for Bax, FasL, Fas, and L-19 genes based on the conserved regions present in mRNA sequences of Homo sapiens, Bos taurus, and Mus musculus. The primers (forward and reverse) and PCR conditions (annealing temperature and PCR cycle number) used were as follows: 5'-TCATCCAGGATCGAGCAGGG-3' and 5'-CGGCCCCAGTTGAAGTTGCC-3' for 237-bp Bax (56 °C and 35 cycles); 5'-CCTGTGGATGACTGAGTACC-3' and 5'-GAGACAGCCAGGAGAAATCA-3' for 128-bp Bcl-2 (53 °C and 35 cycles); 5'-AATAGGTCACCCCAGTCCACCC-3' and 5'-CAGCCCAGTTTCATTGATCACAAGGC-3' for 174-bp FasL (55 °C and 35 cycles); 5'-AGGGGAACGAGTACACAGAC-3' and 5'-GCAAGGGTTACAGTGTTCAC-3' for 178-bp Fas (50 °C and 33 cycles); and 5'-GAAATCGCCAATGCCAACTC-3' and 5'-TCTTAGACCTGCGAGCCTCA-3' for 406-bp L-19 (58 °C and 25 cycles). Ethidium bromide-stained agarose gels displaying PCR products were scanned using UVI-Tech gel documentation system and quantitated using UVI-Band Map software.

Western Blot Analysis
Corpus luteum tissue lysate was prepared as per the previously published procedures (7). Equal amount of luteal tissue lysate (200 µg of protein/lane) was resolved by 10 or 12% SDS-PAGE and electroblotted onto PVDF membrane, and Western blot analysis was performed as per the published procedures. Autoradiographs were scanned using UVI-Tech gel documentation system and quantitated using UVI-Band Map software.

Caspase-8/9 Activity Assays
Caspase-8/9 activity assays were performed using fluorogenic substrates Z-IETD-AFC (caspase-8) and Z-LEHD-AFC (caspase-9). Luteal tissues collected before and after PGF2{alpha} treatment and after coinjection (15 min apart) of caspase inhibitors and PGF2{alpha} were homogenized in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM {beta}-glycerophosphate, and 1 mM Na3VO4). After determining the protein concentration, an equal amount (200 µg) of luteal lysate protein (at non-saturating concentration of the assay, for details see Supplemental Fig. 1) was mixed in 0.5 ml of caspase-8/9 activity assay buffer (100 mM HEPES, pH 7.5, 20% glycerol, 5 mM DTT, and 0.5 mM EDTA) followed by the addition of 20 µM Z-IETD-AFC/10 µM Z-LEHD-AFC substrate. Reaction mixture was incubated at 37 °C for 4–5 h, and liberated AFC was measured in a spectrofluorometer with an excitation wavelength of 400 nm and an emission wavelength of 420–520 nm. The specificity of the caspase-8/9 assay was determined by the addition of caspase-8/9-specific inhibitor Z-IETD-fmk/Z-LEHD-fmk).

Caspase-3 Activity Assays
Caspase-3 activity assays were performed using a fluorogenic substrate, Z-DEVD-AFC. Equal amounts (100 µg) of luteal lysate protein (at non-saturating concentration of the assay, for details see Supplemental Fig. 1) from different time points post-PGF2{alpha} treatment were added to 1 ml of caspase-3 activity assay buffer (20 mM HEPES, pH 7.5, 10% glycerol, and 2 mM DTT) followed by the addition of 20 µM Z-DEVD-AFC substrate. Reaction mixtures were incubated at 37 °C for 1 h, and liberated AFC was measured in a spectrofluorometer with an excitation wavelength of 400 nm and an emission wavelength of 420–520 nm. The specificity of the caspase-3 assay was determined by using caspase-3-specific inhibitor Ac-DEVD-CHO.

Deoxyribonuclease Substrates
Rat liver nuclei were prepared as described previously (41, 42). Rat liver was homogenized in homogenization buffer (15 mM HEPES-NaOH, pH 7.4, 80 mM KCl, 15 mM NaCl, 5 mM EDTA, 1 mM DTT, 0.5 mM spermidine, 0.2 mM spermine, and 1 mM phenylmethylsulfonyl fluoride) containing 250 mM of sucrose in a Dounce homogenizer. The homogenate was filtered through four layers of cheese cloth, and an equal volume of homogenization buffer containing 2.3 M sucrose was added and mixed thoroughly. The homogenate then was layered over 5 ml of homogenization buffer containing 2.3 M sucrose in a Beckman SW28 centrifuge tube and centrifuged at 22,000 x rpm for 90 min at 4 °C. The pellet was resuspended in homogenization buffer at a concentration of ~3 x 106 nuclei/µl and stored at –70 °C. Purified rat nuclei were used as a chromatin substrate for DNase activity assays, whereas the plasmid DNA obtained from pGEMT empty vector was used as a non-chromatin (naked DNA) substrate for DNase activity assays.

Deoxyribonuclease Activity Assays
For DNase assays crude cytosolic extracts were prepared from the luteal tissue essentially as described previously (43, 44). Luteal tissue collected before and at 18 h post-PGF2{alpha} treatment was swollen in an equal volume of extraction buffer (50 mM PIPES, pH 7.4, 50 mM KCl, 5 mM EGTA, 2 mM MgCl2, 1 mM DTT, 20 µM cytochalasin B, 1 µg/ml leupeptin, 1 µg/ml pepstatin A, and 1 mM phenylmethylsulfonyl fluoride) for 10 min followed by five cycles of freezing and thawing, which was accompanied by grinding with a pestle each time. The resultant lysate was then centrifuged at 12,000 x g for 15 min at 4 °C. The supernatant was aspirated, aliquoted, and frozen at –70 °C until use for protein estimation by Bradford (microassay) method. This supernatant was used as crude luteal cytosolic extract for DNase assays. DNase assays were performed according to the previously published procedures (43, 44) with some modifications. For DNase assay, using non-chromatin substrate, 10 µg of plasmid DNA was incubated with 50 µg of crude luteal cytosolic extract at 37 °C for 30 min (with the exception of the time course analysis of DNase activity where assay was terminated at different time points) in a DNase assay buffer (20 mM HEPES, pH 7.5, 1 mM CaCl2, 5 mM MgCl2, 1 mM DTT, and 0.1 mM phenylmethylsulfonyl fluoride if not stated otherwise). For analysis of pH dependence of the DNase activity, using naked DNA as a substrate, different buffers were used that included acetate NaOH, pH 4.0 and 5.0, phosphate buffer, pH 6.0, MOPS-NaOH, pH 6.5, HEPES-NaOH, pH 7.5, and Tris-HCl, pH 8.0 and 9.0, with the other components of the assay buffer remaining the same. Assay was terminated by the addition of 6x loading dye, and samples were analyzed in a 2% agarose gel containing 0.5 µg/ml ethidium bromide.

For DNase assays using chromatin substrate, ~3 x 106 nuclei were incubated with crude luteal cytosolic extract in different pH assay buffers as indicated above for 30 min at 37 °C. Assay was terminated by adding the lysis buffer (50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 0.2 M NaCl, 0.2% SDS, and 0.1 mg/ml proteinase K), and DNA was precipitated after overnight incubation at 37 °C by the addition of an equal volume of isopropyl alcohol. The resultant nucleic acid pellet was dissolved in Tris-HCl, pH 8.0, containing 1 mM EDTA and 0.1 mg/ml RNase A and incubated at 37 °C for 30 min. The DNA was extracted and analyzed by gel electrophoresis using a 2% agarose gel in the presence of 0.5 µg/ml ethidium bromide.

Immunodepletion of Caspase-activated DNase
Immunoprecipitation was carried out by incubating 400 µg of regressing (18 h after PGF2{alpha} treatment) luteal lysate protein with polyclonal anti-CAD antibody or rabbit IgG and protein A-agarose at 4 °C overnight. The pellet containing immune complexes was obtained by centrifugation at 15,000 x g for 10 min at 4 °C. The pellet was diluted in 50 µl of immunoprecipitation buffer, and an aliquot was used in the in vitro DNase activity assay, whereas supernatant was concentrated to a volume of 50 µl and then used in the DNase activity assay. Similar procedures were followed for control IgG supernatant and pellet.

Statistical Analyses
Wherever applicable, the data were expressed as mean ± S.E. The arbitrary densitometric units were represented as the percentage relative to control, which was set at 100%. The data were analyzed by one-way ANOVA followed by Tukey's multiple comparison test (PRISM GraphPad, version 2, GraphPad Software Inc., San Diego, CA). A value of p < 0.05 was considered statistically significant.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Prostaglandin F2{alpha} Injection into Buffalo Cows Induces Luteal Cell Apoptosis in the Corpus Luteum
In situ apoptosis analysis of the luteal tissue collected at different time points after PGF2{alpha} injection showed an increased number of apoptotic cells (small and large luteal cells) 18 h after PGF2{alpha} injection into buffalo cows (Fig. 1B). Although no incidence of apoptosis was observed in the corpus luteum at 4 h, some evidence of apoptosis was present in the corpus luteum at 12 h after PGF2{alpha} injection. These data confirm our previous observation of the time of onset of apoptotic DNA fragmentation during PGF2{alpha}-induced luteolysis (7) and further validate our model for the analysis of apoptotic signaling cascades that culminate in the apoptotic cell death in the corpus luteum.



View larger version (45K):
[in this window]
[in a new window]
  		FIG. 1.
Prostaglandin F2{alpha}-induced apoptosis in the bovine corpus luteum. A, schematic representation of the experimental procedure for PGF2{alpha} treatment and corpus luteum collection in buffalo cows (B. bubalis). Asterisk indicates time of collection of corpus luteum. B, corpora lutea collected from the buffalo cows at different time points after PGF2{alpha} treatment were processed for in situ apoptosis analysis using in situ cell death detection kit (Roche Diagnostics). Arrows indicate apoptotic nuclei. Magnification, x100.

 
Activation of Mitochondrial Apoptotic Signaling Cascade in the Corpus Luteum during PGF2{alpha}-induced Apoptosis
Fig. 2 illustrates changes in steady-state mRNA and protein levels of pro- and anti-apoptotic Bcl-2 family members during PGF2{alpha}-induced luteal tissue apoptosis. Bax (a pro-apoptotic gene) mRNA (Fig. 2A) and protein levels (Fig. 2B) increased within 4 h and remained high at 18 h, the last time point observed, but mRNA and protein levels of Bcl-2 (an anti-apoptotic gene) did not change in the luteal tissue post-PGF2{alpha} treatment (Fig. 2, A and B). Changes in Bax and Bcl-2 mRNA and protein levels were also expressed as Bax/Bcl-2 ratio, an index that is used for the activation or inhibition of the mitochondrial permeability to apoptogenic molecules (Fig. 2C). As can be seen in Fig. 2C, Bax/Bcl-2 ratio, both mRNA and protein levels, increased with a more profound effect on the Bax/Bcl-2 protein ratio as early as 4 h, which remained high until 18 h, suggesting an increase in the mitochondrial permeability to apoptogenic molecules. Immunohistochemical analysis of Bax (Fig. 2D) revealed increased punctate appearance of cells (in the perinuclear region) during PGF2{alpha}-induced luteal tissue apoptosis, a parameter that confirms increased localization of proteins to mitochondria (45). However, IgG control did not show any staining (shown in inset). Bad, another pro-apoptotic Bcl-2 family member that gets activated upon hypophosphorylation, was also examined in the luteal tissue that showed a decrease in the phosphorylation of Bad within 4 h, and the levels remained low at 18 h (Supplemental Fig. 2A). We next determined changes in the active caspase-9 protein levels and activity during PGF2{alpha}-induced luteal tissue apoptosis. As seen in Fig. 3A, active caspase-9 protein levels increased in the luteal tissue 4–12 h after PGF2{alpha} treatment and were highest at 18 h. In vitro caspase activity assays using caspase-9-specific substrate Z-LEHD-AFC essentially corroborated the Western blot analysis results (Fig. 3B). Z-LEHD-fmk (a specific inhibitor of caspase-9) completely abolished the caspase activity observed in the luteal tissue lysates, confirming the specificity of the assay (Fig. 3B).



View larger version (55K):
[in this window]
[in a new window]
  		FIG. 2.
Prostaglandin F2{alpha}-induced changes in Bcl-2 and Bax mRNA and protein levels in the bovine corpus luteum. A, total RNA isolated from the corpora lutea collected before and at different time points after PGF2{alpha} treatment was subjected to semi-quantitative RT-PCR analysis for Bcl-2 and Bax mRNA levels. L-19 mRNA expression was utilized as an internal control. The estimated sizes of PCR products (in bp) are indicated on the left. B, equal amounts of total protein lysates (200 µg/lane) were resolved on a 12% SDS-PAGE and transferred onto PVDF membrane for immunoblotting with Bax and Bcl-2 antibodies. As a control for protein loading, the blot was stripped of the bound antibodies and reprobed with {beta}-actin antibody. The estimated sizes (in kDa) of the protein bands are indicated on the left. C, quantitative changes in the ratio of Bcl-2 and Bax mRNA (A) and Bcl-2 and Bax protein levels (B) in corpora lutea collected before and at different time points after PGF2{alpha} treatment. Mean ± S.E. of three experiments is shown. Bars a and b are significantly different (p < 0.05). D, representative corpora lutea sections of immunohistochemical staining for Bax. Corpora lutea sections from the luteal tissue collected before and at different time points after PGF2{alpha} treatment were rehydrated and incubated with Bax antibody followed by incubation with fluorescein isothiocyanate-conjugated anti-rabbit antibody raised in goat. Sections were mounted in glycerol and visualized under a confocal microscope at x100 (Zoom 1.5). Inset shows immunostaining observed with rabbit IgG (negative control).

 



View larger version (30K):
[in this window]
[in a new window]
  		FIG. 3.
PGF2{alpha}-induced regulation of processed caspase-9 protein levels and activity in the bovine corpus luteum. A, equal amounts of total protein lysate (200 µg/lane) prepared from corpora lutea collected before and at different time points after PGF2{alpha} treatment were resolved on a 12% SDS-PAGE and transferred on to PVDF membrane for immunoblotting. Membrane was probed with antibody that detects endogenous levels of large fragment (37 kDa) of cleaved caspase-9, and the blot was stripped of the bound cleaved caspase-9 antibody and reprobed with {beta}-actin antibody to confirm equal loading of protein across lanes. Mean ± S.E. of cleaved caspase-9 protein levels relative to {beta}-actin are shown below the Western blot image. B, caspase-9 activity assay on luteal tissue lysates using Z-LEHD-AFC as a substrate indicating changes in caspase-9 activity in corpora lutea collected before and at different time points after PGF2{alpha} treatment. Specificity of the assay was checked using caspase-9-specific inhibitor Z-LEHD-fmk (see "Experimental Procedures" for details of the assay). Mean ± S.E. of three experiments is shown. Bars a–c are significantly different (p < 0.05).

 
Activation of Caspase-3 in the Corpus Luteum during PGF2{alpha}-induced Apoptosis
To address whether caspase-9 activation (initiator caspase) was associated with an increase in the activation of downstream target effector caspase, caspase-3, we measured the active form of caspase-3 by Western blot analysis and caspase-3 activity by in vitro caspase-3 activity assay. As shown in Fig. 4A, a dramatic increase in the active caspase-3 protein levels was seen at 18 h. An increase in the active caspase-3 protein levels was associated with an increase in the cleaved form of PARP, an endogenous substrate of caspase-3, and a significant increase (p < 0.05) in the caspase-3 activity in the corpus luteum at 18 h post-PGF2{alpha} treatment (Fig. 4B). The addition of Ac-DEVD-CHO (a specific inhibitor of caspase-3) completely abolished the caspase activity observed in the luteal tissue lysates, confirming the specificity of the assay (Fig. 4B).



View larger version (44K):
[in this window]
[in a new window]
  		FIG. 4.
Prostaglandin F2{alpha}-induced regulation of processed caspase-3 protein levels and activity in the bovine corpus luteum. A, equal amounts of total protein lysate (200 µg/lane) prepared from corpora lutea collected before and at different time points after PGF2{alpha} treatment were resolved on a 12% SDS-PAGE and transferred on to PVDF membrane for immunoblotting. Membrane was probed with antibody that detects endogenous levels of large fragment (19/17 kDa) of cleaved caspase-3. The blot was stripped of the bound caspase-3 antibody and reprobed with {beta}-actin antibody to confirm equal loading of protein across lanes. Cleaved caspase-3 protein levels relative to {beta}-actin are indicated below the Western blot image. Changes in the PARP cleavage as determined by Western blotting before and at different time after PGF2{alpha} treatment is shown. B, caspase-3 activity assay on luteal tissue lysates using Z-DEVD-AFC as a substrate indicating changes in caspase-3 activity in corpora lutea collected before and at different time points after PGF2{alpha} treatment. Specificity of the assay was checked using caspase-3-specific inhibitor Ac-DEVD-CHO (see "Experimental Procedures" for details of the assay). Mean ± S.E. of three experiments is shown. Bars a–c are significantly (p < 0.05) different.

 
Analysis of Extrinsic Apoptotic Signaling Cascade Elements in the Corpus Luteum
Fig. 5 illustrates changes in steady-state mRNA levels of Fas and FasL in the corpus luteum before and at different time points after PGF2{alpha} treatment. As can be seen in Fig. 5A, FasL mRNA expression levels were unchanged in the corpus luteum at 4 and 12 h but the expression was high at 18 h. The Fas receptor mRNA levels were up-regulated in the corpus luteum within 4 h (4.5-fold compared with 0 h) and became low at 12 h (1.4-fold compared with 0 h) but increased again at 18 h (2.3-fold compared with 0 h). An analysis of caspase-8 activation revealed no change at 4–12 h posttreatment, but the activity increased significantly (p < 0.05) at 18 h (Fig. 5C). Z-IETD-fmk (a specific inhibitor of caspase-8) completely abolished the caspase activity observed in the luteal tissue lysates, confirming the specificity of the assay (Fig. 5C). We next determined changes in the cleavage of Bid, a downstream target of caspase-8, that can interact with mitochondria and lead to amplification in the mitochondrial cascade. Immunoblot analysis of truncated Bid (tBid) levels in the corpus luteum is shown in Fig. 5B. Whereas tBid was undetectable at 0, 4 and 12 h, the signal was high at 18 h post-PGF2{alpha} treatment.



View larger version (32K):
[in this window]
[in a new window]
  		FIG. 5.
PGF2{alpha}-induced changes in the extrinsic apoptotic signaling cascade elements in the bovine corpus luteum. A, total RNA isolated from the corpora lutea collected before and at different time points after PGF2{alpha} treatment was subjected to semi-quantitative RT-PCR analysis for FasL and Fas mRNA levels. As a control for RNA amount variation in samples, same cDNA preparation was analyzed for L-19 mRNA levels. The estimated sizes of PCR products (in bp) are indicated on the left. B, Western blot analysis using Bid antibody shows tBid levels in the corpora lutea collected before and at different time points after PGF2{alpha} treatment. Blot was stripped of the bound Bid antibody and reprobed with {beta}-actin antibody for confirmation of equal loading of protein across lanes. C, caspase-8 activity assay on luteal tissue lysates using Z-IETD-AFC as a substrate indicating changes in caspase-8 activity in corpora lutea collected before and at different time points after PGF2{alpha} treatment. Specificity of the assay was checked using caspase-8-specific inhibitor Z-IETD-fmk (see "Experimental Procedures" for details of the assay). Mean ± S.E. of three experiments is shown. Bars a and b are significantly different (p < 0.05).

 
Relative Contribution of Intrinsic and Extrinsic Apoptotic Signaling Cascades in PGF2{alpha}-induced Apoptosis
We next investigated the relative contribution of intrinsic and extrinsic apoptotic signaling cascades in mediating PGF2{alpha}-induced luteal tissue apoptosis. For this purpose, we standardized a pseudopregnant rat model for PGF2{alpha}-induced luteolysis and employed a pharmacological blockade of specific caspases associated with intrinsic and extrinsic apoptotic signaling cascades as well as general caspases using peptide-based, cell-permeable, and irreversible caspase inhibitors. Before analyzing the effects of caspase inhibition on PGF2{alpha}-induced luteal tissue apoptosis in pseudopregnant rats, it was necessary to determine whether PGF2{alpha} treatment activated similar apoptotic signaling cascades in the rat corpus luteum. The experimental design employed in rats is presented in Fig. 6A, and DNA fragmentation analysis, semi-quantitative RT-PCR analysis of upstream activators of intrinsic and extrinsic apoptotic signaling cascades (Bax and FasL, respectively), and changes in caspase-9, -8, and -3 activities during PGF2{alpha}-induced luteal tissue apoptosis are presented in Fig. 6, B–F. As can be seen in Fig. 6B, increased DNA oligonucleosome formation is discernible in the DNA isolated from luteal tissues collected 24 h after PGF2{alpha} injection, indicative of cell death through apoptosis. Semi-quantitative RT-PCR analysis revealed up-regulation in the steady-state mRNA levels of Bax and FasL during PGF2{alpha}-induced apoptosis in the rat luteal tissue (Fig. 6C). We next determined whether increases in the expression of these genes that act upstream of apoptotic signaling cascades are associated with the activation of downstream caspases. The results of caspase activation analysis are presented in Fig. 6, D–F. Ascan be seen from the figures, a significant (p < 0.05) up-regulation in caspase-9 (1.9 ± 0.04-fold versus 0 h), caspase-8 (3.5 ± 0.5-fold versus 0 h), and caspase-3 (4.8 ± 0.3-fold versus 0 h) activities occurred in the luteal tissue following PGF2{alpha} injection. These results suggest striking similarities in the mechanisms of apoptosis initiation in the cow and rat luteal tissue and validate our choice of use of pseudopregnant rat model for examining the relative role of intrinsic and extrinsic apoptotic signaling cascades during PGF2{alpha}-induced luteal tissue apoptosis in vivo.



View larger version (33K):
[in this window]
[in a new window]
  		FIG. 6.
Characterization of apoptotic signaling events during PGF2{alpha}-induced luteal tissue apoptosis in the pseudopregnant rats. A, schematic representation of the experimental procedure for induction of luteal tissue apoptosis in the pseudopregnant rat model. Asterisk indicates time of collection of corpora lutea. B, genomic DNA (30 µg) isolated from corpora lutea obtained 24 h after vehicle or PGF2{alpha} analog injection on day 8 of pseudopregnancy was separated on 2% agarose gel and stained with ethidium bromide. Note the presence of DNA oligonucleosomes in the DNA isolated from PGF2{alpha} treated-animals. C, semi-quantitative RT-PCR analysis of Bax and FasL mRNA levels for vehicle/PGF2{alpha}-treated luteal tissue. L-19 mRNA expression was utilized as an internal control. Bar diagram represents quantitative changes in the mRNA levels relative to L-19. D–F, caspase-9, -8, and -3 activity assays on luteal tissue lysates using substrates specific to respective caspases. For details, see legends to Figs. 3, 4, 5.

 
Fig. 7A represents the experimental design utilized to examine the effect of peptide-based cell-permeable caspase inhibitors (caspase-9 inhibitor (Z-LEHD-fmk), caspase-8 inhibitor (Z-IETD-fmk), and general caspase inhibitor (Z-VAD-fmk)) on PGF2{alpha}-induced luteal tissue apoptosis, and changes in caspase-3 activities and oligonucleosome formation in the luteal tissue are presented in Fig. 7, B–D. Although caspase-9 inhibitor significantly (p < 0.05) decreased PGF2{alpha}-induced caspase-3 activity, DNA oligonucleosome formation was only marginally decreased in the luteal tissue. In contrast, the administration of caspase-8 inhibitor or general caspase inhibitor resulted in dramatic reduction in PGF2{alpha}-induced caspase-3 activity and oligonucleosome formation. These results suggest the requirement of activation of extrinsic apoptotic signaling cascade, which is necessary and sufficient for PGF2{alpha}-induced apoptosis in the luteal tissue, whereas the activation of intrinsic apoptotic signaling cascade alone is insufficient.



View larger version (36K):
[in this window]
[in a new window]
  		FIG. 7.
Effects of caspase inhibitors on PGF2{alpha}-induced changes in the apoptotic signaling in the corpus luteum. A, schematic representation of the experimental procedure to investigate the effect of caspase inhibitors on PGF2{alpha}-induced luteal tissue apoptosis in the pseudopregnant rat model. Asterisk indicates time of collection of corpora lutea. B, determination of caspase-3 activity. DEVDase enzyme activity corresponding to caspase-3 activity was measured in the luteal tissue 24 h after in vivo treatments. 15 min prior to subcutaneous injection of vehicle or PGF2{alpha} treatment, rats received intrabursal injection of vehicle or specific caspase inhibitors (Z-LEHD-fmk, a caspase-9 inhibitor, or Z-IETD-fmk, a caspase-8 inhibitor, or Z-VAD-fmk, a general caspase inhibitor) as described under "Experimental Procedures." Results are presented as arbitrary fluorescence units (AFU). Mean ± S.E. of three experiments is shown. Bars a–c are significantly different (p < 0.05). Different treatments are indicated at the bottom of panel D. C, qualitative changes in DNA fragmentation. DNA (30 µg) isolated from luteal tissue before and 24 h after different treatments (for details, see B) was subjected to agarose gel electrophoresis followed by ethidium bromide staining. Different treatments are indicated at the bottom of the gel. D, quantitative changes in DNA fragmentation. Low molecular weight DNA fragments (panel C) were quantified by densitometric analysis. Results (fold change from vehicle treatment) are presented as arbitrary densitometric units. Mean ± S.E. of three experiments is shown. Bars a–c are significantly different (p < 0.05). Different treatments are indicated at the bottom of the bars.

 
Induction of a Ca2+/Mg2+-dependent DNase Activity in Corpus Luteum during PGF2{alpha}-induced Apoptosis
To examine the DNase activity responsible for apoptotic DNA ladder formation during PGF2{alpha}-induced luteal tissue apoptosis, we analyzed cellular DNase activity in the corpus luteum collected 18 h post-PGF2{alpha}. Before subjecting the PGF2{alpha}-treated tissues for characterization of DNase activity, tissues were analyzed for DNA oligonucleosome formation (Supplemental Fig. 3) to confirm for the presence of DNase activity in corpus luteum collected from the buffalo cows 18 h post-PGF2{alpha} injection. Biochemical characterization of the DNase activity in the crude cytosolic extract of corpus luteum collected 18 h post-PGF2{alpha} treatment indicated that maximum DNase activity was observed under neutral pH conditions (pH 6.5–7.5) (Fig. 8A). DNase activity was found to be dose-dependent, maximum at 50 µg of cytosolic extract (Fig. 8B), and maximum activity was observed at 60 min (Fig. 8C) of the assay under the conditions tested. As shown in the Fig. 8D, the observed DNase activity was inhibited by the addition of EDTA/EGTA, suggesting the requirement of divalent cations Ca2+/Mg2+ by the DNase. Heat treatment inactivated the DNase activity, but RNase was ineffective, suggesting proteinaceous nature of the DNase activity.



View larger version (72K):
[in this window]
[in a new window]
  		FIG. 8.
DNA fragmentation induced by PGF2{alpha}-activated luteal cytosolic extract. A, pH dependence of DNA fragmentation. Equal amount of cytosolic extract protein (50 µg) prepared from the corpus luteum collected at 18 h after PGF2{alpha} treatment was added to the nuclei (3 x 106) from normal rat liver and incubated at 37 °C for 30 min in the DNase assay buffer at the indicated pH values. DNA was extracted and analyzed by agarose gel electrophoresis. The position of standard DNA fragments (in bp) are indicated on the left. B, dose-dependent DNase fragmentation. The cytosolic extract prepared from the corpus luteum collected at 18 h after PGF2{alpha} treatment at the indicated protein amounts was added to the isolated nuclei (3 x 106) from normal rat liver followed by incubation at 37 °C for 30 min in the DNase assay buffer at pH 7.5. DNA was extracted and analyzed by agarose gel electrophoresis. C, time course of DNA fragmentation. Cytosolic extract protein (50 µg) prepared from the corpus luteum collected at 18 h after PGF2{alpha} treatment was added to the isolated nuclei (3 x 106) from normal rat liver and incubated at 37 °C for indicated time periods in DNase assay buffer at pH 7.5. DNA was extracted and analyzed by agarose gel electrophoresis. The standard DNA fragments (lane M) are indicated on the left (in bp). D, Ca2+/Mg2+-dependent protein in the luteal cytosolic extract is responsible for inducing DNA fragmentation. Cytosolic extract protein (50 µg) prepared from the corpus luteum collected at 18 h after PGF2{alpha} treatment was preincubated at 37 °C for 60 min with 100 µg/ml RNase A or 68 °C for 10 min (heat) or 5 mM EGTA + 5mM EDTA at 37 °C for 10 min. Isolated nuclei (3 x 106) from normal rat liver were added to the treated cytosolic extracts and incubated at 37 °C for 30 min in DNase assay buffer, pH 7.5. DNA was extracted and analyzed by agarose gel electrophoresis. As a positive control for DNase activity, cytosolic extract (50 µg) from luteal tissue was incubated with the isolated nuclei (3 x 106) without any preincubation (lane 1).

 
Inhibition of DNase Activity by ICAD
We next examined changes in the ICAD fragmentation during PGF2{alpha}-induced luteal tissue apoptosis. Increased low molecular weight ICAD fragmentation products that corresponded to previously published partial ICAD fragments (46, 47) were observed following PGF2{alpha}-induced apoptosis in the corpus luteum (Supplemental Fig. 4). The chemical properties of DNase in association with the degradation of ICAD suggested that it could be CAD. To examine this possibility, ICAD-L, a specific inhibitor of CAD, was expressed in Escherichia coli as a GST fusion protein and purified as described previously by Nagata and co-workers (14) (Supplemental Fig. 5). This GST-ICAD-L fusion protein was then used in an in vitro DNase assay to examine whether it can inhibit the DNase activity. As shown in Fig. 9, GST-ICAD-L was able to inhibit the DNase activity (oligonucleosome formation in nuclei-based assay and DNA smear formation in plasmid DNA-based assay) observed in the crude cytosolic extract prepared from the luteal tissue collected at 18 h post-PGF2{alpha} treatment in a dose-dependent fashion. Complete inhibition was observed at a dose of 100 ng, whereas GST even at a concentration of 200 ng did not inhibit the DNase activity. GST-ICAD-L was not observed to inhibit DNase I or II activities (data not presented).



View larger version (91K):
[in this window]
[in a new window]
  		FIG. 9.
Inhibition of DNase activity by recombinant ICAD. Equal amounts (50 µg) of cytosolic protein extract prepared from the corpus luteum collected 18 h after PGF2{alpha} treatment were preincubated with the indicated amounts of GST-ICAD-L (lanes 4–13), and the DNase activity was determined with isolated nuclei (3 x 106) from normal rat liver (top panel) or 10 µg of plasmid DNA (bottom panel). The effect of control GST protein on the DNase activity present in the cytosolic protein extract is also shown (lane 14). Lane 2 shows the integrity of the nuclei/plasmid DNA used for the assay, and lane 3 shows DNA fragmentation activity of the cytosolic extract without preincubation with GST/GST-ICAD-L. The position of standard DNA fragments (in bp) are indicated on the left.

 
Induction of Caspase-activated DNase in the Corpus Luteum following PGF2{alpha} Administration
We next addressed the question of whether the ICAD-sensitive DNase activity with a potential to cleave DNA into oligonucleosomes under in vitro conditions was indeed induced during PGF2{alpha}-induced luteal tissue apoptosis. As shown in Fig. 10A, this ICAD-sensitive DNase activity was induced in the corpus luteum by PGF2{alpha} treatment associated with apoptotic DNA fragmentation. To further confirm the identity of the DNase as CAD, we carried out immunodepletion studies with the CAD antibody. These results are presented in Fig. 10B. As can be seen in Fig. 10B, depletion of CAD from the corpus luteum tissue lysate collected 18 h post-PGF2{alpha} treatment abolished the DNA fragmentation activity in the lysate supernatant (Fig. 10, S). When the CAD immune complex pellet (P) was used in the DNase assay, it induced DNA fragmentation and the activity in the pellet was abrogated by the addition of 100 ng of GST-ICAD-L. Although IgG control did not show any activity in the immune complex, the activity was still present in the supernatant, demonstrating the specificity of the immunodepletion experiment. These results confirm the identity of the apoptotic endonuclease, CAD, in mediating the PGF2{alpha}-induced DNA fragmentation in the luteal tissue.



View larger version (58K):
[in this window]
[in a new window]
  		FIG. 10.
Changes in DNA fragmentation activity in luteal tissue during PGF2{alpha}-induced apoptosis. A, equal amount of cytosolic protein extract (50 µg) prepared from the corpus luteum collected before and at 18 h after PGF2{alpha} treatment was added to the 10 µg of plasmid DNA (used as naked DNA substrate; left panel) or to the isolated nuclei (3 x 106) from normal rat liver (used as a chromatin substrate; right panel) and incubated at 37 °C for 30 min in DNase assay buffer, pH 7.5. DNA was extracted and analyzed by agarose gel electrophoresis. The standard DNA fragments (in bp, lane M) are indicated on the left. B, immunodepletion of CAD from luteal tissue lysates. CAD was immunoprecipitated from 400 µg of luteal tissue lysates, and the resultant supernatant (S) and the CAD immune complex pellet (P) were used in the DNase assay as described under "Experimental Procedures." IgG supernatant and pellet were used as a control for the assay. Please note the presence of DNA fragmentation activity in the CAD pellet and abolition of DNA fragmentation activity in the CAD pellet with the addition of 100 ng of GST-ICAD-L.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Prostaglandin F2{alpha} actions on the corpus luteum can be divided into two distinct but interrelated processes, functional and structural luteolysis. The functional luteolysis, which is characterized by rapid reduction in serum/luteal tissue progesterone levels, may be viewed as the commencement of initiation of a new reproductive cycle due to the withdrawal of negative feedback effect of progesterone on the gonadotropin secretion, whereas structural luteolysis that occurs as a consequence of apoptotic cell death is required for resorption of luteal structure in the ovarian stroma (48). Prostaglandin F2{alpha} affects progesterone production either by interfering with the cholesterol transport to the inner mitochondrial membrane (49) or by enhancing catabolism of progesterone (50). In the rat, PGF2{alpha} has been reported to enhance catabolism of progesterone rather than inhibit the synthesis and this action is brought about by the stimulatory effects of PGF2{alpha} on Nur77-mediated increased expression of 20{alpha}-hydroxy steroid dehydrogenase, a key enzyme involved in progesterone catabolism (50). However, in the bovine corpus luteum, PGF2{alpha} does not seem to have a significant effect on the stimulation of 20{alpha}-hydroxy steroid dehydrogenase and it is likely that the PGF2{alpha}-mediated decreased transport of cholesterol to inner mitochondrial membrane is the key mechanism resulting in decreased steroidogenesis (2). It is interesting to note that mitochondria might be playing an important role in PGF2{alpha}-activated signal transduction pathways responsible for decreased steroidogenesis as well as structural luteolysis. In this study, we investigated spatial and temporal changes in the apoptotic signaling cascades in the luteal tissue of the buffalo cow, a bovine species, in which PGF2{alpha} is recognized as the physiological luteolysin. In addition, a pseudopregnant rat model was utilized to investigate the relative contribution of intrinsic (mitochondrial) versus extrinsic (death receptor-mediated) apoptotic signaling cascades in PGF2{alpha}-mediated luteal tissue apoptosis.

Studies carried out in several species have clearly established that apoptosis plays an important role during structural luteal regression (6–10). To elucidate the molecular events associated with the onset of apoptosis, it is necessary to select suitable time points with clear earliest evidence for onset of apoptosis. For this purpose, we employed two methods to determine initiation of apoptosis. The DNA fragmentation analysis reported earlier by us (7) and the in situ apoptosis analysis results reported in this study indicated the onset of apoptosis in the luteal tissue at 18 h post-PGF2{alpha} treatment. To characterize changes leading to the initiation of apoptosis, we included two additional time points (4 and 12 h) earlier to 18 h in which no evidence for apoptosis was evident but, at these time points, the effect of PGF2{alpha} on steroidogenesis was clearly discernible. These results broadly corroborate with the observation made (6–10) by others with regard to the initiation of apoptosis in cattle and other species.

Great strides have been made in the recent years toward a better understanding of the intracellular signaling cascades that regulate the initiation of apoptosis in the cells exposed to apoptotic stimuli. One of the major intracellular signaling pathways that regulate apoptosis during cellular stress is mediated by changes in the Bcl-2 family of proteins that are classified either as anti-apoptotic (Bcl-2, Bcl-XL, and so on) or pro-apoptotic (Bax, Bad, and so on), and it has been proposed that the fate of a cell at any given time is decided by the ratio or balance between the pro-apoptotic and anti-apoptotic members (11). A luteolytic dose of PGF2{alpha} brought about a rapid increase in the Bax levels (mRNA and protein) but without having much effect on the Bcl-2 levels (mRNA and protein), resulting in an increase in the Bax/Bcl-2 ratio. Higher Bax mRNA levels have been observed in the spontaneously regressing bovine corpus luteum by Rueda et al. (24), and the results of this study also confirms the importance of Bax in the luteal regression process and provides evidence for the regulation of Bax expression by PGF2{alpha} in the corpus luteum. Apart from Bcl-2 and Bax, another Bcl-2 family member; Bad, plays an important role during apoptosis and a decrease in the phosphorylation status of Bad has been shown to be associated with the apoptosis in the cells (51). An analysis of luteal tissue revealed hypophosphorylation of Bad as early as 4 h that remained lower thereafter, suggesting its increased pro-apoptotic activity.

We next examined changes in the caspase-9 and -3, the activation of which has been linked to the initiation (caspase-9) and execution (caspase-3) of apoptosis downstream to mitochondria (52). Although the involvement of caspase-9 during luteal tissue apoptosis has not been reported in corpus luteum of any species thus far, several lines of evidence suggest that it plays an important role in the cellular apoptosis via cleavage-mediated activation of its downstream target, caspase-3 (53).

Caspase-3 in turn cleaves several downstream targets involved in cellular homeostasis, viz. PARP, ICAD, and so on. In this study, although the total form of PARP increased in expression at 18 h, the cleaved form of PARP was only found to be up-regulated at 18 h following PGF2{alpha} injection compared with levels in the corpus luteum of control animals, further confirming the activation of caspase-3 in the process. In the murine corpus luteum, Wang et al. (54) have reported increased expression of PARP during PGF2{alpha}-induced luteal tissue apoptosis and this could be due to the increased stability of PARP mRNA or higher protein expression during luteolysis. The involvement of caspase-3 in mediating apoptosis in the mammalian cells is well established (52). Rueda et al. (55) found an increase in the caspase-3 activation in the ovine luteal tissue during PGF2{alpha}-induced luteolysis. Carambula et al. (23) reported that corpus luteum of caspase-3-deficient mice is resistant to PGF2{alpha}-mediated apoptosis that further confirms the involvement of caspase-3 in luteal cell apoptosis. Surprisingly, although the increase in the caspase-9 and -3 activation observed at 4–12 h time points correlated with the expression changes in the Bcl-2 family members (increased Bax levels and decreased phospho-Bad levels), the dramatic induction in their activities at 18 h, particularly that of caspase-3, could not be explained by changes in the expression or localization of the mitochondrial Bcl-2 family members, suggesting the involvement of other pathways in the activation of caspase-3 in addition to caspase-9.

Apart from the intrinsic apoptotic signaling cascade, extrinsic (or death receptor-mediated) apoptotic signaling cascade has been reported to play an important role in the regulation of apoptosis in various cell types exposed to a variety of apoptotic stimuli (12). The finding that Fas expression was increased at different time points post-PGF2{alpha} treatment suggested a role for Fas in luteal tissue apoptosis. Taniguchi et al. (25) also observed increased expression of Fas in the corpus luteum during the late luteal phase, a period in which spontaneous luteolysis would have occurred. However, it has been reported that the expression of Fas alone is not sufficient for inducing cell death and that FasL expression is the key determinant in regulating the activity of Fas in mediating apoptosis (56). The observation that FasL expression was induced in the luteal tissue at 18 h post-PGF2{alpha} treatment suggests the involvement of Fas-FasL in apoptosis of the luteal tissue, further confirmed by the observation of caspase-8 activation, which acts as an initiator caspase downstream to the Fas receptor. In a recent study, Carambula et al. (23) using induced multiple follicular growth and ovulation model reported that PGF2{alpha} can induce the activation of caspase-8 associated with the apoptosis in the murine corpus luteum; however, the upstream death receptor coupled to the activation of caspase-8 was not reported in their study. Our results in rat and bovine corpus luteum provide support for the importance of caspase-8 signaling in the luteal tissue apoptosis and strongly suggest that this is more probable because of the induction of FasL and Fas expression by PGF2{alpha}. Interestingly, the activation of extrinsic apoptotic signaling cascade was observed only at 18 h and this might provide an explanation for the induction in the caspase-3 activity at the 18 h time point because caspase-3 is a downstream target of caspase-8. However, it does not explain the amplification in the mitochondrial cascade observed at 18 h. In this regard, it has been proposed that activated caspase-8 cleaves Bid and that this form (tBid) can amplify the mitochondrial cascade by modulating the ratio of pro-apoptotic to anti-apoptotic members at the level of mitochondria (57). Indeed, the examination of the corpus luteum for tBid levels at different time points post-PGF2{alpha} treatment revealed an induction in the tBid levels only at 18 h, providing possible explanation for amplification in the caspase-9 activity observed at the 18-h time point.

Because it was impractical due to the very large body size (>400 kg), difficulty in accessing ovaries in vivo, and quantity of inhibitors required to mechanistically address the involvement of intrinsic and extrinsic apoptotic signaling cascades in the PGF2{alpha}-induced luteal tissue apoptosis in the bovine model, we investigated the relative contribution of these cascades in PGF2{alpha}-induced luteal tissue apoptosis using a well established pseudopregnant rat model (39, 58). Although PGF2{alpha} has been reported to induce luteolysis in this model (39), the involvement of apoptotic signaling cascades in this model remains poorly characterized. Therefore, we first examined the involvement of intrinsic and extrinsic apoptotic signaling cascades during PGF2{alpha}-induced luteal tissue apoptosis in the pseudopregnant rats. Our results of increased expression of Bax and FasL and activation of caspase-9, -8, and -3 demonstrate for the first time PGF2{alpha}-induced activation of apoptotic signaling cascades in the rat corpus luteum and that this model can be used to study the effect of pharmacological inhibition of activities of different caspases on PGF2{alpha}-induced luteal tissue apoptosis. Two peptide-based, cell-permeable, and irreversible caspase inhibitors were used to inhibit initiator caspase in intrinsic (caspase-9 (Z-LEHD-fmk)) or extrinsic (caspase-8 (Z-IETD-fmk)) apoptotic signaling cascades. In addition, a broad spectrum caspase inhibitor (Z-VAD-fmk) was used to demonstrate the effect of executionary caspase (caspase-1, -3, -4, and -7) inhibition on luteal tissue apoptosis. These peptide-based caspase inhibitors have been demonstrated to inhibit caspase-dependent cell death in various in vivo models of apoptosis, viz. cerebral ischemia (34, 35), myocardial dysfunction in sepsis (36), liver injury (37), and thymic dysfunction in sepsis (38). In this study, the broad spectrum caspase inhibitor inhibited both caspase-3 activation and DNA fragmentation following PGF2{alpha} injection in the luteal tissue. Caspase-8 inhibitor also could reduce PGF2{alpha}-induced caspase-3 activity and DNA fragmentation in the luteal tissue. The levels were similar to those observed in the luteal tissue of vehicle-treated control animals, but caspase-9 inhibitor only had a marginal effect on these parameters. These results suggest that extrinsic apoptotic signaling cascade plays an indispensable role during PGF2{alpha}-induced luteal tissue apoptosis. To our knowledge, this is the first demonstration of activation of classical apoptotic signaling cascades by an atypical death receptor via induction of upstream genes that activate these apoptotic signaling cascades under in vivo conditions. However, the involvement of other death receptors in this process cannot be ruled out because caspase-8 is also known to act downstream of many other receptors that induce cell death such as tumor necrosis factor-{alpha} receptor (56).

DNA fragmentation is an important event in the executionary phase of cellular apoptosis (59). Although several endonuclease-like properties have been reported to be present in the luteal cells (29, 30), the endonuclease responsible for apoptotic DNA fragmentation in response to PGF2{alpha} remains to be identified. We demonstrate the presence of a Ca2+/Mg2+-dependent temperature-sensitive DNase maximally active at neutral pH conditions in the crude cytosolic extract prepared from luteal tissue collected at 18 h post-PGF2{alpha} treatment. Moreover, we show that this putative DNase was induced by PGF2{alpha} and was associated with the DNA fragmentation in the corpus luteum at the 18 h time point. The optimal DNase activity in the luteal cytosolic extract was observed at pH 6.5–7.5, ruling out the possible involvement of alkaline or acidic endonucleases (DNase I/II) or endonucleases that show two pH optima, viz. endonuclease G during PGF2{alpha}-induced apoptotic DNA degradation in the corpus luteum. The biochemical nature of the DNase observed in the regressing corpus luteum was very similar to the properties of CAD reported by Nagata and co-workers (43). Caspase-activated DNase has been reported to be activated during apoptosis by caspase-3-dependent cleavage of its inhibitor (ICAD). The examination of luteal tissue lysates for ICAD by Western blotting revealed increased presence of a ~30-kDa ICAD-reactive product at 12 h that apparently reflects a partially processed intermediate observed by others (43, 47). The partially cleaved ICAD further decreased at 18 h, suggesting that degradation of ICAD at 18 h post-PGF2{alpha} might be responsible for the activation of the caspase-activated DNase in the luteal tissue, resulting in the fragmentation of chromosomal DNA into a 180-bp ladder. We reasoned that, if this were to be true, the addition of exogenously expressed ICAD should be able to abolish the DNase activity observed in the cytosolic extract prepared from PGF2{alpha}-treated luteal tissue. Indeed, the addition of GST-ICAD-L to the DNase assay abolished the DNase activity present in the cytosolic extract. In addition, immunodepletion of CAD from regressing luteal lysates abolished the DNA fragmentation activity observed in the regressing luteal lysates and the DNase activity observed in the immune complex was abolished by the addition of GST-ICAD-L in the DNase assay. Together, these data provide convincing evidence for the involvement of CAD in apoptosis associated with PGF2{alpha}-induced luteal tissue apoptosis.

Based on the findings in this study and studies by others, we propose a model for the PGF2{alpha}-induced apoptotic signaling pathways in the corpus luteum (Fig. 11). Prostaglandin F2{alpha}-induced apoptotic signaling in the corpus luteum involves the activation of stress-activated protein kinases such as JNK and p38 MAPK (7, 60) that have been shown to result in the increased expression of genes that are primary initiators of apoptotic signaling machinery, viz. Bax and FasL/Fas (61). Ligation of the FasL to Fas receptor or changes in the mitochondrial permeability results in the activation of the initiator (caspase-8 and -9) and executionary (caspase-3) caspases. The importance of caspase signaling in mediating luteal tissue apoptosis is further demonstrated in the present study by the use of caspase inhibitors and in a previous study (23) by the absence of luteal apoptosis in response to PGF2{alpha} in caspase-3 knock-out mice. These caspases then cleave key cellular proteins that include ICAD, resulting in the release of CAD followed by the translocation of CAD to the nucleus that executes the DNA fragmentation. These apoptotic luteal cells then are recognized and cleared from the ovarian stroma by immune cells that have been shown to infiltrate in the ovary during luteolysis. In conclusion, the results from this study suggest activation of both intrinsic and extrinsic apoptotic signaling cascades in the corpus luteum in response to PGF2{alpha} treatment and there appears to be distinct phases in which each cascade is initiated but eventually both converge to induce apoptosis.



View larger version (29K):
[in this window]
[in a new window]
  		FIG. 11.
A schematic representation of PGF2{alpha}-activated apoptotic signaling cascades in the bovine corpus luteum. Dashed lines represent the results reported by others, and solid lines represent the results reported in this study. The detailed explanation is provided under "Discussion."

 

   FOOTNOTES
 
* This work was supported in part by grants from the Council of Scientific and Industrial Research, Indian Council of Medical Research, and University Grants Commission (New Delhi, India). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{boxs} The on-line version of this article (available at http://www.jbc.org) contains Supplemental Figs. 1–5. Back

{ddagger} Supported by fellowship from the Council of Scientific and Industrial Research (New Delhi, India). Back

§ To whom correspondence should be addressed: Dept. of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore 560012, India. E-mail: rmm{at}mrdg.iisc.ernet.in.

1 The abbreviations used are: PGFF2{alpha}, prostaglandin F2{alpha}; ICAD, inhibitor of caspase-activated DNase; CAD, caspase-activated DNase; PARP, poly(ADP-ribose) polymerase; PVDF, polyvinylidene difluoride; Z, benzyloxycarbonyl; fmk, fluoromethyl ketone; GST, glutathione S-transferase; RT, reverse transcription; DTT, dithiothreitol; PIPES, 1,4-piperazinediethanesulfonic acid; MOPS, 4-morpholinepropanesulfonic acid; ANOVA, analysis of variance; tBid, truncated Bid; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; AFC, 7-amino-4-trifluoromethylcoumarin; Ac, acetyl; CHO, aldehyde. Back


   ACKNOWLEDGMENTS
 
We are grateful to Professor S. Nagata (Department of Genetics, Osaka University Medical School, Osaka, Japan) for kindly providing us the GST-ICAD-L construct and for discussions during the course of DNase characterization. We thank Professor Kumarvel Somasundaram for the generous gift of general caspase inhibitor (Z-VAD-fmk), Dr. B. R. Srinath and K. R. Shiva Kumar for help with experiments in rats, and T. N. Vivek for help with expression and purification of the recombinant GST fusion proteins.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Pharriss, B. B., Tillson, S. A., and Erickson, R. R. (1972) Recent Prog. Horm. Res. 28, 51–89[Medline] [Order article via Infotrieve]
  2. Niswender, G. D., Juengel, J. L., Silva, P. J., Rollyson, M. K., and McIntush, E. W. (2000) Physiol. Rev. 80, 1–29[Abstract/Free Full Text]
  3. McCracken, J. A., Custer, E. E., and Lamsa, J. C. (1999) Physiol. Rev. 79, 263–323[Abstract/Free Full Text]
  4. Wiltbank, M. C., Diskin, M. G., Flores, J. A., and Niswender, G. D. (1990) Biol. Reprod. 42, 239–245[Abstract]
  5. McGuire, W. J., Juengel, J. L., and Niswender, G. D. (1994) Biol. Reprod. 51, 800–806[Abstract]
  6. Rueda, B. R., Wegner, J. A., Marion, S. L., Wahlen, D. D., and Hoyer, P. B. (1995) Biol. Reprod. 52, 305–312[Abstract]
  7. Yadav, V. K., Sudhagar, R. R., and Medhamurthy, R. (2002) Biol. Reprod. 67, 752–759[Abstract/Free Full Text]
  8. Bacci, M. L., Barazzoni, A. M., Forni, M., and Costerbosa, G. L. (1996) Domest. Anim. Endocrinol. 13, 361–372[CrossRef][Medline] [Order article via Infotrieve]
  9. Juengel, J. L., Garverick, H. A., Johnson A. L., Youngquist, R. S., and Smith, M. F. (1993) Endocrinology 132, 249–254[Abstract/Free Full Text]
  10. McCormack, J. T., Friederichs, M. G., Limback, S. D., and Greenwald, G. S. (1998) Biol. Reprod. 58, 255–260[Abstract/Free Full Text]
  11. Adams, J. M., and Cory, S. (1998) Science 281, 1322–1326[Abstract/Free Full Text]
  12. Nagata, S. (1997) Cell 88, 355–365[CrossRef][Medline] [Order article via Infotrieve]
  13. Martin, S. J., and Green, D. R. (1995) Cell 82, 349–352[CrossRef][Medline] [Order article via Infotrieve]
  14. Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., and Nagata, S. (1998) Nature 391, 43–50[CrossRef][Medline] [Order article via Infotrieve]
  15. Halenbeck, R., MacDonald, H., Roulston, A., Chen, T. T., Conroy, L., and Williams, L. T. (1998) Curr. Biol. 8, 537–540[CrossRef][Medline] [Order article via Infotrieve]
  16. Urbano, A., McCaffrey, R., and Foss, F. (1998) J. Biol. Chem. 273, 34820–34827[Abstract/Free Full Text]
  17. Wyllie, A. H., Kerr, J. F., and Currie, A. R. (1980) Int. Rev. Cytol. 68, 251–306[Medline] [Order article via Infotrieve]
  18. Barry, M. A., and Eastman, A. (1993) Arch. Biochem. Biophys. 300, 440–450[CrossRef][Medline] [Order article via Infotrieve]
  19. Mogil, R. J., Shi, Y., Bissonnette, R. P., Bromley, P., Yamaguchi, I., and Green, D. R. (1994) J. Immunol. 152, 1674–1683[Abstract]
  20. Giannakis, C., Forbes, I. J., and Zalewski, P. D. (1991) Biochem. Biophys. Res. Commun. 181, 915–920[CrossRef][Medline] [Order article via Infotrieve]
  21. Ribeiro, J. M., and Carson, D. A. (1993) Biochemistry 32, 9129–9136[CrossRef][Medline] [Order article via Infotrieve]
  22. Li, L. Y., Luo, X., and Wang, X. (2001) Nature 412, 95–99[CrossRef][Medline] [Order article via Infotrieve]
  23. Carambula, S. F., Pru, J. K., Lynch, M. P., Matikainen, T., Goncalves, P. B., Flavell, R. A., Tilly, J. L., and Rueda, B. R. (2003) Reprod. Biol. Endocrinol. 1, 15[CrossRef][Medline] [Order article via Infotrieve]
  24. Rueda, B. R., Tilly, K. I., Botros, I. W., Jolly, P. D., Hansen, T. R., Hoyer, P. B., and Tilly, J. L. (1997) Biol. Reprod. 56, 186–193[Abstract]
  25. Taniguchi, H., Yokomizo Y, and Okuda, K. (2002) Biol. Reprod. 66, 754–759[Abstract/Free Full Text]
  26. Quirk, S. M., Harman, R. M., Huber, S. C., and Cowan, R. G. (2000) Biol. Reprod. 63, 49–56[Abstract/Free Full Text]
  27. Suter, J., Hendry, I. R., Ndjountche, L., Obholz, K., Pru, J. K., Davis J. S., and Rueda, B. R. (2001) Biol. Reprod. 64, 1481–1486[Abstract/Free Full Text]
  28. Terranova, P. F. (1997) Domest. Anim. Endocrinol. 14, 1–15[CrossRef][Medline] [Order article via Infotrieve]
  29. Zeleznik, A. J., Ihrig, L. L., and Bassett, S. G. (1989) Endocrinology 25, 2218–2220
  30. Boone, D. L., Yan, W., and Tsang, B. K. (1995) Biol. Reprod. 53, 1057–1065[Abstract]
  31. Matousek, M., Mitsube, K., Mikuni, M., and Brannstrom, M. (2001) Mol. Hum. Reprod. 7, 35–42[Abstract/Free Full Text]
  32. Motta, A. B., Estevez, A., and de Gimeno, M. F. (1999) Mol. Hum. Reprod. 5, 1011–1016[Abstract/Free Full Text]
  33. Lara, H. E., Dissen, G. A., Leyton, V., Paredes, A., Fuenzalida, H., Fiedler, J. L., and Ojeda, S. R. (2000) Endocrinology 141, 1059–1072[Abstract/Free Full Text]
  34. Cheng, Y., Deshmukh, M., D'Costa, A., Demaro, J. A., Gidday, J. M., Shah, A., Sun, Y., Jacquin, M. F., Johnson, E. M., and Holtzman, D. M. (1998) J. Clin. Investig. 101, 1992–1999[Medline] [Order article via Infotrieve]
  35. Rabuffetti, M., Sciorati, C., Tarozzo, G., Clementi, E., Manfredi, A. A., and Beltramo, M. (2000) J. Neurosci. 20, 4398–4404[Abstract/Free Full Text]
  36. Fauvel, H., Marchetti, P., Chopin, C., Formstecher, P., and Neviere, R. (2001) Am. J. Physiol. 280, H1608–H1614
  37. Cursio, R., Gugenheim, J., Ricci, J. E., Crenesse, D., Rostagno, P., Maulon, L., Saint-Paul, M. C., Ferrua, B., and Auberger, A. P. (1999) FASEB J. 13, 253–261[Abstract/Free Full Text]
  38. Methot, N., Huang, J., Coulombe, N., Vaillancourt, J. P., Rasper, D., Tam, J., Han, Y., Colucci, J., Zamboni, R., Xanthoudakis, S., Toulmond, S., Nicholson, D. W., and Roy, S. (2004) J. Exp. Med. 199, 199–207[Abstract/Free Full Text]
  39. Bjurulf, E., Toffia, O., Selstam, G., and Olofsson, J. I. (1998) Biol. Reprod. 59, 17–21[Abstract/Free Full Text]
  40. Yadav V. K., Muraly P., and Medhamurthy R. (2004) Mol. Human Reprod. 10, 629–639[Abstract/Free Full Text]
  41. Newmeyer, D. D., and Wilson, K. L. (1991) Methods Cell Biol. 36, 607–634[Medline] [Order article via Infotrieve]
  42. Newmeyer, D. D., Farschon, D. M., and Reed, J. C. (1994) Cell 79, 353–364[CrossRef][Medline] [Order article via Infotrieve]
  43. Enari, M., Hase, A., and Nagata, S. (1995) EMBO J. 14, 5201–5208[Medline] [Order article via Infotrieve]
  44. Martin, S. J., Newmeyer, D. D., Mathias, S., Farschon, D. M., Wang, H. G., Reed, J. C., Kolesnick, R. N., and Green, D. R. (1995) EMBO J. 14, 5191–5200[Medline] [Order article via Infotrieve]
  45. Goldstein, J. C., Waterhouse, N. J., Juin, P., Evan, G. I., and Green, D. R. (2000) Nat. Cell Biol. 3, 156–162
  46. Liu, X., Zou, H., Slaughter, C., and Wang, X. (1997) Cell 89, 175–184[CrossRef][Medline] [Order article via Infotrieve]
  47. Tang, D., and Kidd, V. J. (1998) J. Biol. Chem. 273, 28549–28552[Abstract/Free Full Text]
  48. Niswender, G. D., and Nett, T. M. (1994) The Physiology of Reproduction, 2nd Ed., pp. 781–816, Raven Press, New York
  49. McLean, M. P., Billheimer, J. T., Warden, K. J., and Irby, R. B. (1995) Endocrinology 136, 4963–4972[Abstract]
  50. Stocco, C. O., Zhong, L., Sugimoto, Y., Ichikawa, A., Lau, L. F., and Gibori, G. (2000) J. Biol. Chem. 275, 37202–37211[Abstract/Free Full Text]
  51. Franke, T. F., and Cantley, L. C. (1997) Nature 390, 116–117[CrossRef][Medline] [Order article via Infotrieve]
  52. Thornberry, N. A., and Lazebnik, Y. (1998) Science 281, 1312–1316[Abstract/Free Full Text]
  53. Johnson, C. R., and Jarvis, W. D. (2004) Apoptosis 9, 423–427[CrossRef][Medline] [Order article via Infotrieve]
  54. Wang, Z., Tamura, K., Yoshie, M., Tamura, H., Imakawa, K., and Kogo, H. (2003) J. Pharmacol. Sci. 92, 19–27[CrossRef][Medline] [Order article via Infotrieve]
  55. Rueda, B. R., Hendry, I. R., Tilly, J. L., and Hamernik, D. L. (1999) Biol. Reprod. 60, 1087–1092[Abstract/Free Full Text]
  56. Ashkenazi, A., and Dixit, V. M. (1998) Science 281, 1305–1308[Abstract/Free Full Text]
  57. Li, H., Zhu, H., Xu, C. J., and Yuan, J. (1998) Cell 94, 491–501[CrossRef][Medline] [Order article via Infotrieve]
  58. Prigent-Tessier, A., Tessier, C., Hirosawa-Takamori, M., Boyer, C., Ferguson-Gottschall, S., and Gibori, G. (1999) J. Biol. Chem. 274, 37982–37989[Abstract/Free Full Text]
  59. Compton, M. M. (1992) Cancer Metastasis Rev. 11, 105–119[CrossRef][Medline] [Order article via Infotrieve]
  60. Rueda, B. R., Hendry, I. R., Ndjountche, L., Suter, J., and Davis, J. S. (2000) Mol. Cell. Endocrinol. 164, 59–67[CrossRef][Medline] [Order article via Infotrieve]
  61. Le-Niculescu, H., Bonfoco, E., Kasuya, Y., Claret, F. X., Green, D. R., and Karin, M. (1999) Mol. Cell. Biol. 19, 751–763[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Biol. Reprod.Home page
M. P. Goravanahally, M. Salem, J. Yao, E. K. Inskeep, and J. A. Flores
Differential Gene Expression in the Bovine Corpus Luteum During Transition from Early Phase to Midphase and Its Potential Role in Acquisition of Luteolytic Sensitivity to Prostaglandin F2 Alpha
Biol Reprod, May 1, 2009; 80(5): 980 - 988.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Priyanka, P. Jayaram, R. Sridaran, and R. Medhamurthy
Genome-Wide Gene Expression Analysis Reveals a Dynamic Interplay between Luteotropic and Luteolytic Factors in the Regulation of Corpus Luteum Function in the Bonnet Monkey (Macaca radiata)
Endocrinology, March 1, 2009; 150(3): 1473 - 1484.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
A. Bowolaksono, R. Nishimura, T. Hojo, R. Sakumoto, T. J. Acosta, and K. Okuda
Anti-Apoptotic Roles of Prostaglandin E2 and F2alpha in Bovine Luteal Steroidogenic Cells
Biol Reprod, August 1, 2008; 79(2): 310 - 317.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
J. Komiyama, R. Nishimura, H.-Y. Lee, R. Sakumoto, M. Tetsuka, T. J. Acosta, D. J. Skarzynski, and K. Okuda
Cortisol Is a Suppressor of Apoptosis in Bovine Corpus Luteum
Biol Reprod, May 1, 2008; 78(5): 888 - 895.
[Abstract] [Full Text] [PDF]

Home page
 ReproductionHome page
K. Shirasuna, T. Shimizu, K. Sayama, T. Asahi, M. Sasaki, B. Berisha, D. Schams, and A. Miyamoto
Expression and localization of apelin and its receptor APJ in the bovine corpus luteum during the estrous cycle and prostaglandin F2{alpha}-induced luteolysis
Reproduction, April 1, 2008; 135(4): 519 - 525.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
R. Nishimura, J. Komiyama, Y. Tasaki, T. J. Acosta, and K. Okuda
Hypoxia Promotes Luteal Cell Death in Bovine Corpus Luteum
Biol Reprod, March 1, 2008; 78(3): 529 - 536.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Hamada, S. Tsuchihashi, A. Avanesyan, S. Duarte, C. Moore, R. W. Busuttil, and A. J. Coito
Cyclooxygenase-2 Deficiency Enhances Th2 Immune Responses and Impairs Neutrophil Recruitment in Hepatic Ischemia/Reperfusion Injury
J. Immunol., February 1, 2008; 180(3): 1843 - 1853.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. C. Peluffo, R. L. Stouffer, and M. Tesone
Activity and expression of different members of the caspase family in the rat corpus luteum during pregnancy and postpartum
Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1215 - E1223.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
T. Kisliouk, A. Friedman, E. Klipper, Q.-Y. Zhou, D. Schams, N. Alfaidy, and R. Meidan
Expression Pattern of Prokineticin 1 and Its Receptors in Bovine Ovaries During the Estrous Cycle: Involvement in Corpus Luteum Regression and Follicular Atresia
Biol Reprod, May 1, 2007; 76(5): 749 - 758.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. Stocco, C. Telleria, and G. Gibori
The Molecular Control of Corpus Luteum Formation, Function, and Regression
Endocr. Rev., February 1, 2007; 28(1): 117 - 149.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
V. K. Yadav and R. Medhamurthy
Dynamic Changes in Mitogen-Activated Protein Kinase (MAPK) Activities in the Corpus Luteum of the Bonnet Monkey (Macaca radiata) during Development, Induced Luteolysis, and Simulated Early Pregnancy: A Role for p38 MAPK in the Regulation of Luteal Function
Endocrinology, April 1, 2006; 147(4): 2018 - 2027.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
K. A Slot, M. Voorendt, M. de Boer-Brouwer, H. H van Vugt, and K. J Teerds
Estrous cycle dependent changes in expression and distribution of Fas, Fas ligand, Bcl-2, Bax, and pro- and active caspase-3 in the rat ovary
J. Endocrinol., February 1, 2006; 188(2): 179 - 192.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
280/11/10357    most recent
M409596200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yadav, V. K.
Right arrow Articles by Medhamurthy, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yadav, V. K.
Right arrow Articles by Medhamurthy, R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement